Early Cell Therapy Results in Parkinson’s Show Measurable Gains

Unixell Biotech, a company based in China, has reported encouraging early results from its experimental cell therapy, UX-DA001, designed to restore dopamine-producing neurons in the brains of people with Parkinson’s disease. In a Phase 1 trial led by Professor Liu Jun at Ruijin Hospital, a woman with moderate to severe Parkinson’s who struggled despite four daily medications received cell transplants made from her own induced pluripotent stem cells. Three months later, her motor scores had improved by nearly 50% in the “off” state and 42% in the “on” state. She also experienced over five fewer hours of daily “off” time and better sleep, mood, and urinary control. Brain scans confirmed the transplanted cells were alive and functioning, showing dopamine activity in the targeted area. No serious side effects linked to the therapy were reported, and only mild, short-lived surgical effects such as headache or dyskinesia were observed. The study uses a dual-layer approach, combining symptom scores with imaging evidence to verify real biological change. Unixell’s technique focuses on producing a highly pure batch of dopamine-making cells from each patient’s own tissue, eliminating the need for immune-suppressing drugs. Preclinical tests in animals found no signs of tumour growth and showed strong neuron survival. The ongoing trial will include more participants aged 50 to 75 and test two doses of the therapy. The company hopes its cell preparation method will make transplantation quicker and more reliable. Several other groups are exploring similar cell-based approaches. BlueRock Therapeutics (US/Germany), supported by Bayer, has begun trials using donor-derived stem cells, while Aspen Neuroscience in the US is also testing personalised iPSC-based treatments. Research teams in Japan and Sweden have been studying stem-cell grafts for Parkinson’s for more than a decade, with early evidence of safety and modest clinical benefit. Although UX-DA001’s first patient results are promising, experts caution that it is too early to draw conclusions. The trial’s small size and short follow-up mean further data are essential before knowing whether this approach could become a practical treatment. If the benefits hold up across more patients and longer observation, this type of cell therapy may eventually offer a new route to replace lost neurons rather than simply manage symptoms.